Literature DB >> 16625823

GW-501516 GlaxoSmithKline/Ligand.

Patricia Pelton1.   

Abstract

GlaxoSmithKline and Ligand are developing GW-501516, a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. Phase II clinical trials of this compound are ongoing.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16625823

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  12 in total

Review 1.  Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs.

Authors:  José Iglesias; Ludis Morales; George E Barreto
Journal:  Mol Neurobiol       Date:  2016-03-17       Impact factor: 5.590

Review 2.  PPAR delta agonists and metabolic diseases.

Authors:  Kihwa Kang; Ben Hatano; Chih-Hao Lee
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

3.  PPARδ induces estrogen receptor-positive mammary neoplasia through an inflammatory and metabolic phenotype linked to mTOR activation.

Authors:  Hongyan Yuan; Jin Lu; Junfeng Xiao; Geeta Upadhyay; Rachel Umans; Bhaskar Kallakury; Yuhzi Yin; Michael E Fant; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Res       Date:  2013-06-27       Impact factor: 12.701

4.  Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line.

Authors:  Jennifer E Foreman; Arun K Sharma; Shantu Amin; Frank J Gonzalez; Jeffrey M Peters
Journal:  Cancer Lett       Date:  2009-08-05       Impact factor: 9.756

5.  Expression profiling of peroxisome proliferator-activated receptor-delta (PPAR-delta) in mouse tissues using tissue microarray.

Authors:  Hiroyuki Higashiyama; Andrew N Billin; Yuji Okamoto; Mine Kinoshita; Satoshi Asano
Journal:  Histochem Cell Biol       Date:  2007-03-02       Impact factor: 2.531

6.  Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes.

Authors:  Michael G Borland; Jennifer E Foreman; Elizabeth E Girroir; Reza Zolfaghari; Arun K Sharma; Shantu Amin; Frank J Gonzalez; A Catharine Ross; Jeffrey M Peters
Journal:  Mol Pharmacol       Date:  2008-08-07       Impact factor: 4.054

7.  Ligand-activated peroxisome proliferator-activated receptor β/δ modulates human endometrial cancer cell survival.

Authors:  J J Ma; D Monsivais; M T Dyson; J S Coon; S Malpani; M Ono; H Zhao; H Xin; M E Pavone; J J Kim; D Chakravarti; S E Bulun
Journal:  Horm Cancer       Date:  2013-08-14       Impact factor: 4.667

8.  Alternative splicing of human peroxisome proliferator-activated receptor delta (PPAR delta): effects on translation efficiency and trans-activation ability.

Authors:  Kerstin Lundell; Petra Thulin; Anders Hamsten; Ewa Ehrenborg
Journal:  BMC Mol Biol       Date:  2007-08-16       Impact factor: 2.946

9.  PPARgamma and PPARdelta as Modulators of Neoplasia and Cell Fate.

Authors:  Robert I Glazer; Hongyan Yuan; Zhihui Xie; Yuzhi Yin
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

10.  PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

Authors:  Ancha Baranova
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.